Health-related quality of life in patients aged 6-18 years with chronic hepatitis C treated with sofosbuvir/velpatasvir
- PMID: 37735963
- DOI: 10.1111/liv.15744
Health-related quality of life in patients aged 6-18 years with chronic hepatitis C treated with sofosbuvir/velpatasvir
Abstract
Background & aims: The aim of this study was to assess the effect of treatment with sofosbuvir/velpatasvir (SOF/VEL) on the health-related quality of life (HRQL) of children with chronic hepatitis C.
Methods: In the non-commercial, non-randomized, open-label PANDAA-PED study, 50 children aged 6-18 years with chronic hepatitis C were treated with a fixed dose of SOF/VEL. All patients achieved sustained virologic response 12 weeks after the end of treatment (SVR12). Evaluation of HRQL was performed twice: at baseline (before the treatment) and during the SVR12 analysis using the KIDSCREEN-27 questionnaires, which included 5 dimensions of HRQL, for child self-reporting and parent proxy reporting. The normal range for the population was set to T values of 50 ± 10 points. Child-parent agreement was analysed using the intra-class correlation coefficient (ICC) and Bland-Altman test.
Results: Mean T values were within the normal range for all dimensions, both before and after treatment. There was a significant improvement in physical well-being based on the children's self-assessment (from 48.53 to 51.21, p = .03). In addition, a trend towards better scores in the 'social support & peers' part of the parent proxy evaluation (from 45.98 to 48.66, p = .06) was noticed. After the treatment, the proportion of children self-assessing their physical well-being as below normal significantly decreased from 17% to 5% (p = .007). HRQL scores were not associated with patients' sex, but in most cases, younger age correlated with better HRQL. Evaluation of the ICC for child self-reports versus parent proxy reports revealed poor to moderate agreement for most single measures. Bland-Altman analysis showed that in all dimensions, both before and after treatment, the limits of agreement (LoAs) exceeded ±5 points (half of the SD and considered a maximum allowed difference).
Conclusions: A significant proportion of children with chronic hepatitis C have decreased HRQL in all dimensions, but effective treatment with SOF/VEL leads to an improvement in some areas of well-being. As the effect of HCV on HRQL is more pronounced in older patients, treatment of younger children should be indicated to prevent them from experiencing decreased HRQL due to ongoing HCV infection in the future.
Keywords: children; health-related quality of life; hepatitis C virus; sofosbuvir/velpatasvir.
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Similar articles
-
Health-related Quality of Life in Children and Adolescents After Successful Treatment of Chronic Hepatitis C With Sofosbuvir/Velpatasvir: One-year Outcomes.Pediatr Infect Dis J. 2025 May 1;44(5):405-410. doi: 10.1097/INF.0000000000004675. Epub 2024 Dec 20. Pediatr Infect Dis J. 2025. PMID: 39774052 Free PMC article.
-
Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.Liver Int. 2023 Sep;43(9):1871-1878. doi: 10.1111/liv.15637. Epub 2023 Jun 8. Liver Int. 2023. PMID: 37288719 Clinical Trial.
-
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.PLoS One. 2019 Apr 4;14(4):e0214795. doi: 10.1371/journal.pone.0214795. eCollection 2019. PLoS One. 2019. PMID: 30946776 Free PMC article.
-
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Expert Opin Pharmacother. 2017 Apr;18(5):535-543. doi: 10.1080/14656566.2017.1282459. Epub 2017 Mar 24. Expert Opin Pharmacother. 2017. PMID: 28092171 Review.
-
Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):483-490. doi: 10.1080/17425255.2017.1292253. Epub 2017 Feb 20. Expert Opin Drug Metab Toxicol. 2017. PMID: 28165830 Review.
Cited by
-
Health-related Quality of Life in Children and Adolescents After Successful Treatment of Chronic Hepatitis C With Sofosbuvir/Velpatasvir: One-year Outcomes.Pediatr Infect Dis J. 2025 May 1;44(5):405-410. doi: 10.1097/INF.0000000000004675. Epub 2024 Dec 20. Pediatr Infect Dis J. 2025. PMID: 39774052 Free PMC article.
References
REFERENCES
-
- Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5(4):374-392.
-
- Younossi Z, Papatheodoridis G, Cacoub P, et al. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25(Suppl 3):6-14.
-
- Centers for Disease Control and Prevention. Accessed July 5, 2023. https://www.cdc.gov/hrqol/index.htm
-
- Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790-800.
-
- Weinstein AA, Kallman Price J, Stepanova M, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics. 2011;52(2):127-132.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials